Abstract 4581
Background
The definitive treatment for localized SCCA is ChRT in combination with infusional 5-FU. A meta-analysis of published studies conducted by our group showed that HIV-positive patients (pts) are less cured by ChRT. However, short follow up times may have underestimated the true response rate of HIV-positive pts. We aimed to compare the timing to achieve CR between HIV-negative and positive pts and outcomes according to chemotherapy regimen (Nigro vs ACT2).
Methods
Retrospective multicenter comparative cohort of consecutive pts with histological diagnosis of SCCA and localized disease who received definitive ChRT. Pts’ characteristics and outcomes were compared according to HIV status. The primary endpoint was CR rate defined by absence of clinical and radiological evidence of disease.
Results
A total of 179 patients with SCCA were included: 43 (24%) were HIV-positive and 136 (76%) were HIV-negative. HIV-positive pts were more commonly men: 28 (65%) vs 24 (17.6%) (p < 0.001) and had clinical stage III: 22 (51%) vs 60 (44%). The overall CR rate was 74.4% vs 83.1% for HIV-positive and negative pts, respectively (P = 0.206). Among pts who achieved a CR (N = 145), the rates of CR for HIV-positive vs negative pts were, respectively: 32.5% vs 67% at 6 months evaluation and 41.8% vs 16.1% after 6 months (6 to 18 months) post ChRT (p < 0.001). More HIV-positive pts underwent salvage surgery: 14 (35.2%) vs 21 (15.4%) (p < 0.01). The overall CR rates of HIV-positive pts were 71.4% (10 out of 14) with ACT2 and 63% (14 out of 22) with Nigro. For HIV-negative, the CR rates were: 90.3% (28 out of 31) for ACT2 and 80.2 % (73 out of 91) for Nigro.
Conclusions
Delayed CR was more frequently observed among HIV-positive pts. This finding has clinical implications because waiting longer to define CR among these pts may prevent unnecessary anorectal amputations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract